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Serial Testing for Tuberculosis
In many high-income countries 
with low rates of tuberculosis (TB), 
serial testing for latent TB infection 
(LTBI) is recommended for persons 
at increased risk of TB exposure. For 
example, periodic screening of health 
care workers for LTBI is an important 
component of nosocomial TB infection 
control programs. Serial testing is 
also performed during household 
contact investigations. However, the 
conventional tuberculin skin test (TST) 
has known limitations in accuracy and 
reliability [1,2]. Furthermore, the 
interpretation of serial TST results is 
particularly complicated because of 
non-speciﬁ  c variations in test results, 
boosting, conversions, and reversions 
(see Glossary for deﬁ  nitions) [3]. In 
this context, the development of more 
speciﬁ  c, in vitro assays for LTBI—
interferon gamma (IFNγ) release assays 
(IGRAs)—is a welcome development. 
These assays are highly speciﬁ  c, 
especially in bacillus Calmette Guérin 
(BCG)-vaccinated populations [4,5].
Use of T Cell Assays for Serial 
Testing
In theory, IGRAs have features that 
make them ideal for serial testing. They 
are more speciﬁ  c than TST, can be 
repeated any number of times without 
sensitization and boosting, the testing 
protocol requires only one visit, and 
unlike the TST, there is no need for 
a baseline two-step testing protocol 
to avoid misclassifying TST increases 
due to boosting as true conversions 
due to new infection. Furthermore, 
there is some evidence, although not 
consistent, that IGRAs may be better 
at detecting recent rather than remote 
infection [6].
Are these theoretical advantages 
borne out in real-life studies? Until 
recently, longitudinal data were lacking 
on performance of IGRAs in serial 
testing. In this context, the new study 
by Philip Hill and colleagues, published 
in PLoS Medicine [7], is a valuable 
addition to the existing literature on 
IGRA performance in serial testing 
[8–11]. By serially testing a fairly large 
number of exposed contacts in a high-
prevalence country (i.e., The Gambia), 
the authors have shown that IGRA, 
speciﬁ  cally ELISPOT, conversions 
and reversions frequently occur after 
Mycobacterium tuberculosis exposure.
In order to interpret and use IGRAs 
in serial testing, we need evidence 
on several key questions [4,6,12]: (1) 
What is the reproducibility of T cell 
responses over time (within-subject 
variations over time)? (2) What is an 
IGRA “reversion,” and what threshold 
should be used to deﬁ  ne reversion? 
What is the clinical signiﬁ  cance and 
prognosis of an IGRA reversion? (3) 
What is an IGRA “conversion,” and 
what threshold (cut-off) should be used 
to deﬁ  ne conversion? How can IGRA 
conversions be distinguished from 
nonspeciﬁ  c (random) variations in T 
cell responses over time? (4) What is 
the prognosis of an IGRA conversion? 
Are individuals with strong conversions 
(i.e., large increases in IFNγ responses 
over time) at higher risk of progression 
to active disease than individuals with 
weak conversions or negative results? 
(5) Will treatment of individuals with 
IGRA conversions reduce their risk of 
progression to active disease?
Unfortunately, none of the published 
studies provide strong evidence on 
any of these and other key questions 
(Box 1). For example, there are 
virtually no data on the reproducibility 
of IGRAs, particularly with regard 
to within-subject variability of T cell 
responses during serial testing [6]. 
There are limited data on how much 
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Linked Research Article
This Perspective discusses the following 
new study published in PLoS Medicine:
Hill PC, Brookes RH, Fox A, Jackson-
Sillah D, Jeffries DJ, et al. (2007) 
Longitudinal assessment of an ELISPOT 
test for Mycobacterium tuberculosis 
infection. PLoS Med 4(6): e192. 
doi:10.1371/journal.pmed.0040192
Philip Hill and colleagues report that 
both ELISPOT conversion and reversion 
occur after M. tuberculosis exposure in an 
endemic country and that the ELISPOT 
tests results agree poorly with results 
from the tuberculin skin test.PLoS Medicine  |  www.plosmedicine.org 0981
IFNγ responses will increase following 
new infection and how to differentiate 
this increase from changes due to test-
related error or nonspeciﬁ  c biological 
variations over time. Without such data, 
the results of serial IGRA testing will be 
difﬁ  cult to interpret [6].
Existing studies, including the 
study by Hill and colleagues, clearly 
demonstrate that conversions, 
reversions, and nonspeciﬁ  c variations 
occur with IGRA serial testing, just as 
they do with TST serial testing (Table 
1) [7–11]. Serial testing studies show 
that IGRAs are highly dynamic tests 
and that T cell responses, especially 
weakly positive responses, tend to 
ﬂ  uctuate over time, even in the 
absence of speciﬁ  c treatment [7–11]. 
Although limited, available data 
suggest that positive IGRA results 
vary more than negative results. 
This variation is expected, because 
positive results have room to vary on 
both sides, while negative results are 
constrained to vary between zero and 
the diagnostic cut-off (which is set 
low in commercially available assays). 
Overall, IGRAs may be inherently 
prone to conversions and reversions, 
and this dynamic characteristic raises 
the concern that these assays may be 
too labile or unstable to be used in 
serial testing. Many of the published 
serial testing studies have been done 
in high-incidence countries. It is 
unclear whether similar ﬁ  ndings will 
be seen in countries where exposure 
to TB and other nontuberculous 
mycobacteria is less frequent. Clearly, 
we have yet to fully understand the 
various forces that drive or modulate T 
cell responses.
IGRA Reversions and Their 
Prognosis
An interesting ﬁ  nding in the Gambian 
study is the high rate of reversions 
among household contacts, even 
within a time span of three months and 
despite the newness of exposure [7]. 
Previous studies have also found high 
reversion rates with IGRAs [8,9,11]. In 
general, reversions are least likely when 
baseline IFNγ responses are strong and 
concordantly positive (i.e., positive by 
both TST and IGRA). Concordantly 
positive individuals are likely to 
have very strong IFNγ responses. 
Consequently, unless their responses 
drop dramatically, reversions are not 
likely. In contrast, IGRA reversions 
are more likely when the baseline test 
results are discordant (i.e., positive by 
IGRA but negative by TST) [7–9,11]. 
Discordant results are often weakly 
positive, and weakly positive IFNγ 
levels are likely to be just above the 
diagnostic threshold. Therefore, even 
minor nonspeciﬁ  c variations around 
the threshold can lead to apparent 
reversions.
Why do IGRA reversions occur? 
Some reversions may reﬂ  ect clearing 
of TB infection (spontaneous or due 
to treatment). Some reversions may 
merely be due to biological variations 
among IGRA positive individuals, 
and some reversions may be due 
to variability in laboratory and test 
procedures. Hill and colleagues suggest 
that IGRA responses are inherently 
transient and generally require 
continued exposure to TB antigens to 
maintain high frequencies [7]. They 
argue that reversions may simply reﬂ  ect 
the life cycle of M. tuberculosis, where 
the mycobacterium enters a dormant 
state in which it may not reliably 
secrete antigens such as early secreted 
Table 1. Comparison of TST and IGRA with Respect to Various Serial Testing 
Characteristics
Test or Operational Characteristic TST IGRA
Prone to nonspeciﬁ  c variations in test results 
over time?
Yes Yes (limited data)
Prone to conversions? Yes Yes (conversion rates appear to be high 
when a simplistic negative-to-positive 
deﬁ  nition is used to deﬁ  ne conversion)
Thresholds for deﬁ  ning conversions based 
on evidence?
Yes No
Prone to reversions? Yes Yes (reversion rates are particularly high 
in individuals with weakly positive IGRA 
results and discordance with TST)
Prone to boosting? Yes No
Requirement for baseline two-step testing 
protocol for serial testing?
Yes No
Conversions associated with risk of 
progression to active disease?
Yes (strong evidence) No direct evidence, but limited 
indirect evidence suggests that high 
and/or rising IFNγ responses may be 
associated with progression to disease
Treatment of individuals with conversions 
reduces risk of progression to active TB 
disease?
Yes (strong evidence) No evidence
doi:10.1371/journal.pmed.0040208.t001
Boosting of TST: Boosting of TST upon 
retesting in the absence of new infection 
is immunologic recall of pre-existing 
hypersensitivity to TB (i.e., recall of waned 
immunity).
Conversion: Conversion is the 
development of new immunological 
reactivity (i.e., increase in TST or IFNγ 
responses) following new infection with 
M. tuberculosis.
Reversion: A previously positive TST 
or IGRA result becomes negative upon 
repeat testing (i.e., decrease in TST or 
IFNγ responses).
Threshold for diagnosis of TB 
infection: Cut-off used to detect 
existing latent TB infection with a one 
time screening. With TST, cut-offs vary 
according to risk (e.g., 5, 10, and 15 
mm). With IGRA, the cut-offs depend on 
the type of assay and varies between 
commercial and in-house assays.
Threshold for conversion: Cut-off used 
to detect new TB infection during serial 
testing. With TST, conversion is usually 
deﬁ  ned as a second TST induration of at 
least 10+ mm and an increase of ≥6 mm 
(some guidelines suggest an increase 
of ≥10 mm). With IGRA, the commonly 
used deﬁ  nition is a change from negative 
to positive, but this simplistic deﬁ  nition 
does not specify the amount of increase 
over the baseline IFNγ level.
Discordance between TST and IGRA: 
Disagreement between the two test 
results; for example, TST is positive but 
IGRA is negative.
Glossary of Key Terms
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antigen target 6 (ESAT-6) and culture 
ﬁ  ltrate protein 10 (CFP-10), but instead 
secrete other antigens (which are not 
used in currently available IGRAs) [7]. 
Alternatively, ESAT-6 and CFP-10 may 
be secreted intermittently over the life 
cycle of M. tuberculosis, which may partly 
explain the variations over time [7]. 
These hypotheses are worthy of further 
study.
In routine practice, IGRA-positive 
individuals will not undergo repeated 
testing (just as TST positive individuals 
do not usually get retested). In that 
case, do reversions matter outside the 
setting of research? Probably not, until 
we learn more about the signiﬁ  cance 
and prognosis of IGRA reversions. Do 
IGRA reversions indicate clearance 
or resolution of TB infection? Are 
individuals with reversions susceptible 
to new infections? Unfortunately, our 
existing knowledge base is insufﬁ  cient 
to answer these questions. Cohort 
studies are needed to deﬁ  ne the 
prognosis of IGRA reversions (and 
conversions). Such studies are ongoing 
and will help to settle unanswered 
questions [13].
IGRA Conversions and Their 
Signiﬁ  cance
Although a fairly high rate of IGRA 
conversions has been documented 
in high-risk populations in highly 
endemic settings [8,11], there is 
no consensus on how to deﬁ  ne and 
interpret conversions. Data are lacking 
on key questions, such as: How much 
increase in IFNγ indicates a true new 
infection, and how much is merely test 
or biological variability? Should the 
same threshold be used for diagnosis 
of LTBI as well as conversions (see 
Box 1)? If not, what is the ideal data-
driven approach to deriving cut-offs for 
conversions?
Some studies show that if a simplistic 
negative-to-positive cut-off is used to 
deﬁ  ne conversions, conversion rates 
may be higher with IGRAs than with 
TSTs [8,11]. This higher conversion 
rate could indicate higher sensitivity 
for conversions (not necessarily 
for diagnosis of LTBIs). However, 
some proportion of this higher 
conversion rate is probably due to 
minor nonspeciﬁ  c variations around 
the diagnostic cut-off. For example, 
if the ELISPOT spot count increased 
from just below the cut-off to a level 
just above, is that a real conversion? A 
more stringent cut-off for conversion 
may help avoid misclassifying minor 
variations as conversions [8]. The use 
of a stringent cut-off for conversion 
would be analogous to the TST 
threshold for conversion, which 
requires an increase of at least 6 mm of 
induration above the baseline value to 
an induration of at least 10 mm [3].
None of the existing studies, 
including the study by Hill and 
coworkers, have used data-derived 
cut-offs based on amount of 
Box 1. Outstanding Research 
Questions for Longitudinal and 
Serial Testing Studies
What is the amount of random, biological 
variability of IFNγ responses over time, 
within the same individuals, including 
day-to-day, week-to-week, and month-
to-month variability of IFNγ levels in the 
absence of TB exposure?
For serial testing with IGRAs, which 
threshold for IFNγ (cut-off point) is 
optimal for distinguishing between 
true infection (i.e., conversion) and 
nonspeciﬁ  c, random variation?
How should an IGRA reversion 
be deﬁ  ned, how commonly do 
reversions occur, and what is the 
clinical/epidemiological signiﬁ  cance of 
reversions? What factors are associated 
with IGRA reversions, including 
treatment, baseline IFNγ levels, and 
variability around cut-off points?
Among individuals with positive IGRA 
results, are those with strong and/or 
rising IFNγ responses at greater risk 
for progressing to active disease? Is 
it possible to identify an IGRA cut-off 
point that is predictive of incipient or 
subclinical TB disease?
Among those screened with serial TST 
and IGRA, what is the concordance 
between IGRA and TST conversions? 
What is the correlation between changes 
in absolute TST reactions and IFNγ levels?
Will treatment of IGRA-positive subjects 
(or IGRA conversions) reduce the future 
probability of active TB?
Adapted with permission from reference 
[6].
doi:10.1371/journal.pmed.0040208.g001
Figure 1. A Schematic of the Postulated Correlation between Bacterial Load, T Cell Response, 
and Clinical Outcome
Initial infection might be controlled at its onset with minimal bacterial replication (measured as 
colony-forming units [CFU]) and induction of ESAT-6 responses (A and D). In such cases, the T cell 
response may be below the diagnostic cut-off. However, in most cases, initial bacterial replication 
reaches a point at which it induces an ESAT-6-speciﬁ  c IFNγ response to increase above the 
established cut-off value (infection threshold), enabling the diagnosis of an individual as latently 
infected (B and E). In most cases, individuals control the infection, resulting in latent infection, 
but some develop active TB disease associated with progressive bacterial replication. This is 
accompanied by increasing and strong ESAT-6 responses and, as hypothesized here, an incipient 
(higher) disease cut-off value may predict subsequent development of progressive disease (C and 
F).
Reproduced with permission from [13].
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variation in T cell responses over 
time, an important area for future 
research (Box 1). Until additional 
data become available, health 
professionals who interpret serial 
IGRA testing must learn to critically 
interpret continuous IFNγ values, 
and not merely rely on dichotomous 
(positive/negative) results. To facilitate 
such interpretation, laboratories 
should report continuous as well as 
dichotomous results.
Prognosis of IGRA Conversions 
and Potential Use of IGRAs as a 
Predictive Test
With the TST, the risk of development 
of active TB has been established in 
several cohort studies (reviewed in 
[1]). Also, from controlled clinical 
trials, we know that treatment of TST-
positive persons reduces the risk of 
active disease [14]. This knowledge has 
resulted in guidelines for targeted TST 
testing and treatment for LTBI [14]. 
Unfortunately, there are no equivalent 
data for IGRAs. Although the data 
are limited to one small study [15], of 
an association between strong IFNγ 
response to ESAT-6 and subsequent 
progression to active TB among 
household contacts of index cases, the 
prognosis of a positive IGRA result has 
yet to be determined (Box 1).
What is the prognosis of an IGRA 
conversion? Conversion implies recent 
infection and the prognosis for recent 
(incident) infection is expected to 
differ from the prognosis of already 
existing (prevalent) infection. 
Furthermore, the prognosis of a “strong 
conversion” may well be different from 
that of a “weak conversion.” There 
are no data that directly answer the 
question of prognosis of conversions, 
but emerging data suggest that 
responses to both ESAT-6 and CFP-
10 correlate closely with bacterial 
replication in vivo and with progression 
from infection to disease [6,13].
Recently, Andersen and colleagues 
hypothesized that high and/or rising 
levels of IFNγ produced in response 
to ESAT-6 by T cells from recently 
TB-infected individuals may signal 
incipient disease and thus might serve 
as a prognostic marker for subsequent 
development of overt clinical disease 
in the near future (Figure 1) [13]. 
They reviewed animal and human 
studies that provide preliminary 
evidence that individuals with recent 
exposure have vigorous increases in T 
cell responses, probably due to active 
bacterial replication [13]. Because it 
is well documented that individuals 
with recent TST conversions have 
a high likelihood of progressing to 
active disease, it is plausible that strong 
increases in IFNγ responses after recent 
exposure might predict progression 
to active disease. Thus, instead of 
using IGRAs only as dichotomous 
tests, the actual IFNγ level or rising 
levels (i.e., conversion) may allow the 
identiﬁ  cation of a subgroup among 
infected individuals who may be in 
the process of developing active TB. 
If conﬁ  rmed in large-scale cohort 
studies, this approach may allow for 
more targeted treatment to prevent 
active disease among latently infected 
individuals.  
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